Shared and separate functions of polo-like kinases and aurora kinases in cancer
The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
From Regulatory mechanisms that control mitotic kinesins (2015) · cites this paper as [56]
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000 · cited 1×
“Well-known examples of these drugs are those that perturb the formation of the mitotic spindle such as taxanes and vinca alkaloids”
BackgroundEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315 · cited 1×
“Once proper chromosome alignment is established, cyclin B and securin are degraded by the anaphase-promoting complex/cyclosome bound to CDC20 (APC/C CDC20”
BackgroundTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216 · cited 1×
“Oncogenic activity Overexpression of aurora kinase A induces oncogenic transformation in immortalized rodent fibroblast”
BackgroundDitchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., & Taylor, S. S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208091 · Cited by 1,194 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundHauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., & Peters, J.-M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208092 · Cited by 1,155 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“Most recently, tumour cell lines carrying a KRAS-G13D mutation were shown to be hypersensitive to inhibition of PLK1 (Ref”
Background
Cited by
Items 501–600 of 609
Wu, R., Deng, X., Wang, X., Li, S., Su, J., & Sun, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36561 · Cited by 3
“PLK1 is a central kinase that coordinates diverse mitotic phases and is indispensable to its cancer-driving role in malignant cells [20].”
BackgroundChen, H., Maxwell, C. A., & Connell, M. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_2 · Cited by 3
Alassaf, S. A., Hijjawi, M. S., Abuhammad, A., & Taha, M. O. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02774-x · Cited by 3
Im, C. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0870-1 · Cited by 3
“Overexpression and amplification of Aurora A kinase are involved in the inactivation of apoptosis in tumor cells via interaction with the anti-apoptotic effector NF-jB, and thereby contribute to the development of ovarian, breast, colon, and pancreatic cancer (Jayanthan et al. 2014; Lapenna and Giordano 2009; Lens et…”
BackgroundWang, Z., Ma, Z., & Cao, J. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2297 · Cited by 4
“22,23 24–27 Aurora-A is considered negatively regulated ciliary dynamics in proliferating cells.”
Garon, E. B., & Dubinett, S. M. (2011) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000407560.61287.3f · Cited by 3
Yang, Z., Mogre, S., Jun, H., He, R., Chaudhary, S. G., Bhattarai, U. R., Sui, S. J. H., Matulonis, U. A., Lazo, S., Shetty, A., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0028 · Cited by 2
Aurora‐A Promotes Cell‐Cycle Progression From Quiescence Through Primary Cilia Disassembly
Kohso, A., Inaba, H., Kanemaki, M. T., Gabazza, E. C., Toyoda, H., Hirayama, M., & Goto, H. (2025) · Cancer Science · doi:10.1111/cas.70153 · Cited by 2
Mao, C., Chai, X., He, H., Zhu, J., Li, J., Ma, H., Li, X., & Ye, X. (2025) · Human Cell · doi:10.1007/s13577-025-01266-z · Cited by 3
“[15] AURKA, a serine/ threonine kinase, is crucial for regulating cell mitosis and tumor progression, [25] cytoplasmic division and spindle formation [26, 27], and is abnormally expressed in colorectal cancer [28].”
Yum, Y. A., Jang, S. C., Kim, S. W., Jarhad, D. B., Aswar, V. R., Tripathi, S., Bae, E. S., Choi, H., Yu, J., Lee, S. K., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109146 · Cited by 2
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
González‐Borja, I., Alors‐Pérez, E., Amat, I., Alonso, L., Viyuela-García, C., Goñi, S., Reyes, J. C., Ceballos-Chávez, M., Hernández-García, I., Sánchez‐Frías, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.720128 · Cited by 2
“Structurally, CHFR is a 664 amino acids nuclear protein that has different functional domains: (1) an N-terminal forkhead-associated (FHA) domain that checks the phosphorylation status of specific threonine residues of target proteins (11); (2) a central RING-finger (RING) domain with ubiquitination activity that is n…”
BackgroundPatient, W. N. N., Zhong-hua, S., Ntiak, A., & Apeku, E. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.126015 · Cited by 2
“PLK1 plays a role in cell division, regulating stability in the cell division process and responding to DNA damage [23] [24].”
BackgroundIkura, M., Shiraki, T., Ikura, T., & Furuya, K. (2025) · The Journal of Biochemistry · doi:10.1093/jb/mvaf027 · Cited by 2
Piwocka, K., Wolanin, K., Kusio-Kobiałka, M., & Podszywalow‐Bartnicka, P. (2011) · InTech eBooks · doi:10.5772/25780 · Cited by 2
“any of them has tremendous consequences for cell physiology (Lens et al., 2010).”
Jung, S., Lee, H. S., Shin, H., Choi, J. S., Kim, S. J., & Ku, B. (2023) · The Journal of Microbiology · doi:10.1007/s12275-023-00071-3 · Cited by 2
“All crystallographic data are presented in Table 1.”
BackgroundIshimoto, K., Nakaoka, K., Yabe, O., Nishiguchi, A., & Ikemoto, T. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.08.020 · Cited by 2
p21-activated kinase 4 regulates mitotic spindle positioning and orientation
Bompard, G., & Morin, N. (2012) · BioArchitecture · doi:10.4161/bioa.21132 · Cited by 2
“In this general scheme, the activity of mitotic kinases such as Auroras and Plk1 (Polo-like kinase 1) is crucial.(4) Recently, the p21-activated kinases (PAKs) emerged as novel important players in mitotic progression.”
BackgroundThe toxicity of dysregulated Plk1 activity revealed by its suppressor mutations
Kamakura, N., Takahashi, M., & Jo, M. (2023) · Genes to Cells · doi:10.1111/gtc.13032 · Cited by 1
“…a serine/threonine kinase, is a pivotal regulator in cell cycle progression and involved in multiple mitotic events including condensation and segregation of chromosomes, spindle assembly, and cytokinesis (Barr et al., 2004; Bruinsma et al., 2012; Lens et al., 2010; Petronczki et al., 2008).”
BackgroundDegraders of cell cycle- and antiapoptosis-related proteins
Zhang, Y., Dong, R., & Zhang, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00002-6 · Cited by 1
Bioinformatics analysis identifies AURKB as a prognostic biomarker across multiple human cancers
Xie, H., Wu, A., Xie, M., Chen, S., Huang, Y., Wen, H., Li, H., Fu, Z., & Zheng, W. (2026) · Discover Oncology · doi:10.1007/s12672-025-04105-7 · Cited by 1
Impact of Chromosomal Instability and Aneuploidy in Cancer Development
Mennie, A. K., Dhital, B., & Ly, P. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071124-101613 · Cited by 3
“Cancers with CIN often dysregulate mitotic kinases, such as Aurora A, Aurora B, and PLK1, which correlates with poor prognosis and further implicates mitotic fidelity as a critical vulnerability (Lens et al. 2010, Malumbres 2011, Sen et al. 2002, Sotillo et al. 2007).”
Khanam, H., Dar, A. M., & Dar, B. A. (2025) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-025-10660-6 · Cited by 1
Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer
Ma, Y., Li, Y., & Li, K. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70197 · Cited by 1
Huang, Z., Jiang, T., Palacios, M. M. S., Ouyang, T., Abdallah, A. S., Niu, L., Chen, J., Zhai, X., Ciolak, E., Qiang, W., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218771 · Cited by 2
Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma
Ahrens, A. K., Chaturvedi, N. K., Shukla, A., Nordgren, T. M., Hegde, G. V., Vose, J. M., & Joshi, S. S. (2013) · Lymphoma · doi:10.1155/2013/782903 · Cited by 2
Bibi, N., Hupp, T. R., Kamal, M. A., & Rashid, S. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527999200901201837 · Cited by 1
Mitosis Targets as Biomarkers in Cervical Cancer
Berumen-Campos, J., Espinosa-García, A. M., Medina, I., & Guardado-Estrada, M. (2014) · Springer eBooks · doi:10.1007/978-94-007-7744-6_25-1 · Cited by 1
Liu, N., Hu, N., Fan, C., Tong, M., Shi, X., Wang, H., Sun, P., Mu, S., Qi, Z.-H., Sun, W., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117867 · Cited by 1
Vadlakonda, R., Enaganti, S., & Nerella, R. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i2.14974 · Cited by 1
Targeting Cell Cycle Proteins in Brain Cancer
Ferry, I., Kuzan-Fischer, C. M., Ernoult, E., & Rutka, J. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00019-x · Cited by 1
Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1
Li, Z., Zhang, Z., Sun, H., Xu, L., & Jiang, C. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103148 · Cited by 1
“the inhibition of Plk1 PBD is considered to be an effective method of inhibiting Plk1, which can avoid related specificity problems [11,12].”
MethodYin, Y., Zhou, Y., Yang, X., Xu, Z., Yang, B., Luo, P., Yan, H., & He, Q. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2177151 · Cited by 1
Adaptive fitness in APC -mutant cells requires chromosome rearrangementsPreprint
Kawasaki, Y., Hamaji, T., Owada, K., Hayashi, A., Wu, Y., Nogi, T., Okada, M., Sakai, S., Tokushige, N., Sasagawa, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.18.303016 · Cited by 1
Chen, Q., Zhang, M., Pan, X., Zhou, L., Yan, H., & Wang, F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.01.429225 · Cited by 1
“A number of proteins, including CENP-U and Bub1, are reported to be Plk1 receptors at centromere/kinetochore (Combes et al, 2017, Lens et al, 2010, Lera et al, 2016, Singh et al, 2021).”
BackgroundOrion: Towards Lab Automation with Computer-Using AgentsPreprint
Ma, C., Trinh, L. T., Bucci, M., Regev, A., & Wang, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.13.732095 · Cited by 1
Oliveira, V. L., & Foijer, F. (2015) · BioEssays · doi:10.1002/bies.201400212
“While Aurora B inhibitors are showing promising results in clinical trials [4], targeted CSC inhibitors would potentially trigger fewer side effects, and might therefore have great therapeutic potential.”
BackgroundMitotic Kinase Aurora B is Frequently Overexpressed in Aggressive B-Cell Lymphoma
Hegyi, K., Bedekovics, J., Dócs, O., Irsai, G., Gergely, L., Beke, L., & Méhes, G. (2015) · University of Debrecen Electronic Archive (University of Debrecen)
Requirements for CPC localization during anaphase
van de Moosdijk, A. A. A. (2013) · Utrecht University Repository (Utrecht University)
Mitosis Targets as Biomarkers in Cervical Cancer
Berumen-Campos, J., Espinosa, A. M., Medina, I., & Guardado, M. (2015) · Biomarkers in disease · doi:10.1007/978-94-007-7681-4_25
Hitting cancer where it hurts most
Kuiken, H. J. (2012) · Utrecht University Repository (Utrecht University)
Inhibiting Cell Cycle Kinases in Cancer Therapy
de Cárcer, G., de Castro, I. P., & Malumbres, M. (2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608054640113060009 · Cited by 2
“[159]”
BackgroundInfluentialCaldwell, J. T. (2014) · Human Biology
The spindle assembly checkpoint as a drug target - Novel small-molecule inhibitors of Aurora kinases
Salmela, A.-L. (2012) · UTUPub (University of Turku)
Grundlagen der gastrointestinalen Tumorerkrankungen
Schmelzle, M., Jonas, S., Strumberg, D., Kaufmann, A., Aretz, S., Pietsch, U., Kaisers, U. X., Monz, K., Hartmann, K.-A., Hübner, J., et al. (2015) · Springer eBooks · doi:10.1007/978-3-642-14301-4_28 · Cited by 1
LIMK1 regulates centrosome integrity and mitotic spindle positioning
Ou, S. (2015) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/65350
“AurkA is important for recruiting proteins for centrosome maturation and spindle formation (Barr and Gergely, 2007; Lens et al., 2010; Terada et al., 2003).”
BackgroundAurora-A in transitional cell carcinoma of urinary bladder
Hafez, F. S., Mahmoad, N. B., Fawzy, R. A., Cousha, H. S., & Abu-Zeid, R. M. (2016) · Egyptian Journal of Pathology · doi:10.1097/01.xej.0000482437.08143.a7
“Among them, aurora kinases play a prominent role as essential regulators of the mitotic spindle and have been attributed a wide range of functions in mitotic control (Lens et al., 2010).”
BackgroundIdentification of Mitotic Blockers by Phenotypic Screening of a Clinical Compound Library
Son, Y. H., Park, C. H., & Choi, S. U. (2016) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.10999 · Cited by 1
Robert, J. (2014) · Springer eBooks · doi:10.1007/978-3-319-14340-8_17
Screening of FOXD3 targets in lung cancer via bioinformatics analysis
Jiang, W., Liu, P., & Li, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7685
“AURKA and NOS3 serve important roles in the development of various types of cancer, including lung cancer; AURKA is a cell cycle‑regulated kinase involved in spindle formation and chromosome segregation (42).”
Heberle, A. M. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Identification and characterization of novel drugs for the treatment of pediatric gliomas
Ajeawung, N. F. (2014) · Corpus Université Laval (Université Laval)
Target Therapy in Acute Myeloid Leukemia
Graklanov, V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94422
Bucko, P. J. (2020) · ResearchWorks at the University of Washington (University of Washington)
Investigating the Role of CDK11 in Animal Cytokinesis
Panagiotou, T. C. (2020) · TSpace (University of Toronto)
Annunziata, C. M., & Dennis, P. A. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_1
PTEN: Sumoylation Function is the Key to the Maintenance of Genomic Stability of Cell
Ghosh, G., Misra, S., & Karmakar, P. (2022) · Nano LIFE · doi:10.1142/s1793984422500039
Pediatric Glioblastoma Therapies Based on Patient-Derived Stem Cell Resources
Paddison, P. J. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada622192
Lee, K. S., & Park, J. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13271964.14627066
Introducing Targeted Cancer Treatments
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch2
Millar, J. B. A., & Buttrick, G. J. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13293968.14657077
Knockdown of KIF3C Inhibits Epithelial-Mesenchymal Transition in Lung Cancer Cells A549
Liu, H., Liu, R., Hao, M., Zhao, X., & Li, C. (2022) · Journal of Clinical and Nursing Research · doi:10.26689/jcnr.v6i5.4360
“54 Volume 6; Issue 5 that move along microtubule tracks, and are involved in intracellular molecular transport and mitosis ([12,13]).”
BackgroundTargeting the Complex Protein Network of MYCN-amplified Anaplastic Ependymoma: A Case Report
Castro, M. P. (2022) · Journal of Cellular Signaling · doi:10.33696/signaling.3.082
Lian, A. T., & Chircop, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.30064-5
Faisal, A., Vaughan, L. S., Bavetsias, V., Sun, C., Atrash, B., Avery, S., Jamin, Y., Robinson, S. P., Workman, P., Blagg, J., et al. (2023) · doi:10.1158/1535-7163.c.6535437
Hong, L. V. (2011) · theses.fr (ABES) · doi:10.70675/bc58a0faza3d5z42f3zbf3bz39e1d2879efa · Cited by 1
Hitting the mitotic spot of fibrolamellar carcinoma
Finger, R., Thomas, C. J., Hendriks, D. F. G., & Artegiani, B. (2025) · Gut · doi:10.1136/gutjnl-2025-335566
“15 Sole PLK1 therapy typically yields only partial responses, and PLK1-based combination therapies with, for example, chemotherapy treatments, have shown superior antitumour effects.”
MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1
Lin, M., Pan, Y., Han, S., Zhu, L., Ye, P., Ye, M., & Fang, Z. (2025) · European journal of medical research · doi:10.1186/s40001-025-02825-8
“PLK1 primarily maintains mitosis, regulates spindle assembly and chromosome separation, and promotes DNA replication [13, 14].”
Xia, Y., Chang, Y., Guan, L., Geng, Y., Zhang, Q., Shen, X., Bu, Q., Niu, M., & Han, G. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2514677
“PlK1 plays an important role in the precise maintenance of genome stability in response to mitosis, spindle assembly and DNa damage 10,11 . sufficient evidence suggests that PlK1 mediates the phosphorylation process of dozens of proteins such as cyclin B, cdc25c, tctP and BubR1 12 .”
Almasi, M., Pereira, J. G. N., Dandekar, T., Dandekar, G., & Balkenhol, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7825090/v1
Study of the phosphorylation and activation of the protein kinase NEK9 during mitosis
Domingo, B., & Teresa, M. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Mancini, M., Monaldi, C., Santis, S. D., Papayannidis, C., Rondoni, M., Sartor, C., Bruno, S., Pagano, L., Criscuolo, M., Zanotti, R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22626367
Additional file 1 of BORA regulates cell proliferation and migration in bladder cancer
Cheng, S., Peng, T., Zhu, X., Zhou, F., Wang, G., Ju, L., Xiao, Y., Liu, X., & Wang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12618177
Miao, R., Liu, J., Yue, W. U., Xiang, Y., Yin, B., Zhou, C., Huang, K., Wang, G., Hou, Y., Yuan, L., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109438
Sawant, P., Jain, R., & Dandekar, P. P. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108030
Targeted Therapy-Induced Chromosomal Instability Dictates Mitotic Dependency on Aurora Kinase APreprint
Li, C., Nangia, V., Vieira, M. D., Nimbalkar, A., Graser, C. J., Chang, J. B., Syed, M. U., Shen, Y., Koranne, R., Zou, L., et al. (2026) · SSRN Electronic Journal · doi:10.64898/2026.01.22.701085
Li, G., & Chen, G. (2026) · Discover Oncology · doi:10.1007/s12672-026-04660-7
“…proliferation-related genes implicated in cancer biology, AURKA (Aurora Kinase A) plays a critical role in centrosome maturation, spindle assembly, and mitotic progression, with overexpression linked to chromosomal instability and tumor aggressiveness across multiple cancer types including HCC [9].”
Volasertib in Cancer Therapy: From Mechanism to Clinical Potential
Lambe, S., Lokhande, A., Patil, V. V., Zanan, S., & Waje, R. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1819569
“8,14,15 Several PLK inhibitors have entered clinical development, among which volasertib, rigosertib, and onvansertib have received the greatest attention, particularly in hematologic malignancies such as AML.”
Kumar, A., Chutia, H., & Nagamani, S. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109365
Targeting ubiquitin receptor protein UBASH3B for future cancer therapies
Awal, S. (2019) · theses.fr (ABES) · doi:10.70675/39cb0a92zb4c7z4776za85azed5f4d7cef51
Lee, Y., & Lee, S.-Y. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00537-0
Gustafson, D. L., Early, K., Morales, M. A., Poplawski, K. A., Das, S., & Duval, D. L. (2026) · Veterinary and Comparative Oncology · doi:10.1111/vco.70074
“Further, AurAK and PLK1 play reciprocal roles in the regulation of each other [32], but despite this interaction, there was no correlation in response to these agents.”
Sun, Z., Liang, M., Liu, X., Zhu, H., Zhang, J., Hu, P., Lin, B., Liang, X., Zhang, Z., Li, R., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9364108/v1
Kumar, R., Muthukrishnan, S., Ravi, A. K., Gunasangkaran, G., Arumugam, V. A., Arockianathan, P. M., Packiaraj, G., & Arun, M. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10784-8
Oukhdouch, A., Nadir, Y., Salman, E. M., Khalid, J., Zinbi, B., Souad, S., & rais, H. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2026.100724
Jung, D., Kendi, A. T., Woodrum, D. A., Adamo, D. A., Thompson, S. M., In, M., Bilgin, G. B., Johnson, D. R., Horn, I. M., Kim, E.-J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156899
3D tissue model to patient atlas: dynamic network topology reveals PDAC chemoresistance bottlenecks
ALMASI, M., Pereira, J. G. N., Dandekar, T., Dandekar, G., & Balkenhol, J. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00830-z
BindingDB (2021) · UC San Diego · doi:10.7270/q27p92x1
BindingDB (2024) · UC San Diego · doi:10.7270/q24f1vx5
BindingDB (2023) · UC San Diego · doi:10.7270/q2x63rwz
BindingDB Entry 50020040: Development of MPS1 Inhibitors: Recent Advances and Perspectives.
BindingDB (2024) · UC San Diego · doi:10.7270/q2fr021h
Metadata
- Authors
- Lens, S. M. A., Voest, E. E., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Lens, Susanne M. A.
- Medema, René H.
- Venue
- Nature Reviews Cancer
- Published
- 2010-11-24
- Volume
- 10
- Issue
- 12
- Pages
- 825-841
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1994488152
- Cited by
- 597
- References
- 227
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 10 · 2023: 28 · 2022: 24 · 2021: 29 · 2020: 42 · 2019: 37 · 2018: 27 · 2017: 33 · 2016: 36 · 2015: 56 · 2014: 59 · 2013: 64 · 2012: 65
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- Polo-like kinase, Aurora kinases, PLK1, AURKA, Aurora B kinase, mitosis, kinase inhibitors, anticancer agents, off-target effects, chemosensitization, targeted therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Chromatids, Humans, Mitosis, Neoplasms, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases, Kinetochores, Cell Cycle Proteins, Protein Kinase Inhibitors, Cytokinesis, Aurora Kinase A, Aurora Kinase B, Aurora Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.